PE20050692A1 - Compuestos organicos - Google Patents

Compuestos organicos

Info

Publication number
PE20050692A1
PE20050692A1 PE2005000154A PE2005000154A PE20050692A1 PE 20050692 A1 PE20050692 A1 PE 20050692A1 PE 2005000154 A PE2005000154 A PE 2005000154A PE 2005000154 A PE2005000154 A PE 2005000154A PE 20050692 A1 PE20050692 A1 PE 20050692A1
Authority
PE
Peru
Prior art keywords
hydroxy
ethyl
alkyl
phenyl
alcoxyl
Prior art date
Application number
PE2005000154A
Other languages
English (en)
Inventor
Robin Alec Fairhurst
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20050692A1 publication Critical patent/PE20050692A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

REFERIDA A UN MEDICAMENTO QUE COMPRENDE: A) UN COMPUESTO DE FORMULA I DONDE X ES R1-Ar-R2, Ra-Y; Ar ES FENILO, ALCOXILO C1-C10, ALQUILO C1-C10, ENTRE OTROS; R1 Y R2 ESTAN UNIDOS A ATOMOS DE C ADYACENTES EN AR, Ra ES ENLACE, ALQUILENO C1-C10, ALCOXILO C1-C10, ENTRE OTROS; Y ES ALQUILO C1-C10, ALCOXILO C1-C10, ALQUENILO C2-C10, ENTRE OTROS; Y, B) UN CORTICOSTEROIDE TAL COMO DIPROPIONATO DE BECLAMETASONA, BUDESONIDA, PROPIONATO DE FLUTICASONA, ENTRE OTROS. TAMBIEN REFERIDA A LA PREPARACION DE UN MEDICAMENTO CUYOS COMPUESTOS PREFERIDOS PARA (A) SON: 4-HIDROXI-7-(1-HIDROXI-2-{2-[4-(4-FENIL-BUTOXI)FENIL]ETIL-AMINO)-1-HIDROXI-ETIL]-4-HIDROXI-3H-BENZOTIAZOL-2-ONA; FORMATO DE 4-HIDROXI-7-{(R)-1-HIDROXI-2-[2-(5,6,7,8-TETRAHIDRONAFTALEN-2-IL)-ETIL-AMINO]-ETIL}-3H-BENZOTIAZOL-2-ONA; ENTRE OTROS. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS U OBSTRUCTIVAS DE LAS VIAS RESPIRATORIAS
PE2005000154A 2004-02-09 2005-02-09 Compuestos organicos PE20050692A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0402797.5A GB0402797D0 (en) 2004-02-09 2004-02-09 Organic compounds

Publications (1)

Publication Number Publication Date
PE20050692A1 true PE20050692A1 (es) 2005-11-15

Family

ID=31985893

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000154A PE20050692A1 (es) 2004-02-09 2005-02-09 Compuestos organicos

Country Status (13)

Country Link
EP (1) EP1715860A1 (es)
JP (1) JP2007522141A (es)
KR (1) KR20060127974A (es)
CN (1) CN1917875A (es)
AR (1) AR047962A1 (es)
AU (1) AU2005210140A1 (es)
BR (1) BRPI0507544A (es)
CA (1) CA2552938A1 (es)
GB (1) GB0402797D0 (es)
PE (1) PE20050692A1 (es)
RU (1) RU2006132195A (es)
TW (1) TW200536533A (es)
WO (1) WO2005074924A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200738658A (en) 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
TW200740781A (en) * 2005-08-29 2007-11-01 Astrazeneca Ab Novel compounds
TW200738659A (en) * 2005-08-29 2007-10-16 Astrazeneca Ab Novel compounds
CA2627982C (en) 2005-11-10 2013-09-10 Nicholas S. Bodor Soft anticholinergic esters
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
TW200745067A (en) * 2006-03-14 2007-12-16 Astrazeneca Ab Novel compounds
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
GB0702458D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 668
GB0702456D0 (en) * 2007-02-08 2007-03-21 Astrazeneca Ab New combination
EP2011534A1 (en) * 2007-07-03 2009-01-07 CHIESI FARMACEUTICI S.p.A. Metered dose inhaler actuator
WO2009069032A2 (en) 2007-11-30 2009-06-04 Pfizer Limited Novel glucocorticoid receptor agonists
CA2709071C (en) 2007-12-14 2016-11-15 Labogroup S.A.S. Delivering aerosolizable food products
WO2009087224A1 (en) 2008-01-11 2009-07-16 Novartis Ag Pyrimidines as kinase inhibitors
JP2011524896A (ja) 2008-06-18 2011-09-08 アストラゼネカ・アクチエボラーグ 呼吸器障害の処置用のベータ２−アドレナリン受容体アゴニストとして作用するベンズオキサジノン誘導体
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
WO2012116217A1 (en) 2011-02-25 2012-08-30 Irm Llc Compounds and compositions as trk inhibitors
JO3192B1 (ar) * 2011-09-06 2018-03-08 Novartis Ag مركب بنزوثيازولون
RU2745748C2 (ru) 2016-06-02 2021-03-31 Эббви Инк. Агонист глюкокортикоидного рецептора и его иммуноконъюгаты
MA49796A (fr) 2017-12-01 2020-06-03 Abbvie Inc Agoniste du récepteur des glucocorticoïdes et immunoconjugués de celui-ci

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009018A1 (fr) * 1997-08-14 1999-02-25 Kirin Beer Kabushiki Kaisha DERIVES DE BENZOTHIAZOLONE PRESENTANT UNE ACTIVITE SELECTIVE D'AGONISTE DU RECEPTEUR β2
PE20050130A1 (es) * 2002-08-09 2005-03-29 Novartis Ag Compuestos organicos

Also Published As

Publication number Publication date
AR047962A1 (es) 2006-03-15
RU2006132195A (ru) 2008-03-20
GB0402797D0 (en) 2004-03-10
BRPI0507544A (pt) 2007-06-12
CN1917875A (zh) 2007-02-21
EP1715860A1 (en) 2006-11-02
AU2005210140A1 (en) 2005-08-18
JP2007522141A (ja) 2007-08-09
KR20060127974A (ko) 2006-12-13
TW200536533A (en) 2005-11-16
WO2005074924A1 (en) 2005-08-18
CA2552938A1 (en) 2005-08-18

Similar Documents

Publication Publication Date Title
PE20050692A1 (es) Compuestos organicos
RU2324687C2 (ru) Производные бензотиазола, характеризующиеся агонистической активностью к бета-2-адренорецепторам
ATE440834T1 (de) Substituierte arylaminderivate und verwendungsverfahren
AR063706A1 (es) Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
NO20080865L (no) Spirokromanonderivater som acetyl-koenzym-A-karboksylase(ACC)inhibitorer
JP2006524660A5 (es)
DE602005016929D1 (de) Liganden für den cannabinoidrezeptoren
EA200701780A1 (ru) Противоопухолевое средство
ECSP088099A (es) Nuevos derivados de la 2-azetidinona para el tratamiento de enfermedades hiperlipidémicas
NO20082077L (no) Spirosykliske quinazolinderivater som PDE7-inhibitorer
MXPA04009784A (es) Tiazolidin-4-carbonitrilos y analogos y su uso como inhibidores de dipeptidil-peptidas.
ATE517882T1 (de) Chinolinderivate
TW200833675A (en) Nicotinamide derivatives
EA200970585A1 (ru) Бензамидные производные как агонисты ер-рецепторов
WO2008019967A3 (en) Phenyl, pyridine and quinoline derivatives
EA201101671A1 (ru) Замещенные производные аминопропионовой кислоты в качестве ингибиторов неприлизина
AR063707A1 (es) Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmacéuticas que las comprenden.
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
ATE528306T1 (de) Benzoxazepin-verbindungen, ihre herstellung und verwendung
RU2011133128A (ru) Противоопухолевые соединения дигидропиран-2-она
JP2013528659A5 (es)
JP2016508145A5 (es)
ATE492534T1 (de) 1h-indol-5-ylpiperazin-1-ylmethanonderivate
EA200500095A1 (ru) Производные 4-(7-гало-2-хино(кса-)линилокси)феноксипропионовой кислоты в качестве противоопухолевых средств
AR054888A1 (es) Derivados de quinolina como agentes antibacterianos

Legal Events

Date Code Title Description
FC Refusal